NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. (NAMS) is a healthcare company (biotechnology) based in the Netherlands. The share price is $19.30, down 0.82% on the day, which values the company at $2.31B. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.

Key facts

Share price
$19.30−0.82% today
Market value
$2.31B
Funk Score
27/100
Against its own history
Well above its usual priceusual price $14.83
200-week average
$21.4410% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

NewAmsterdam Pharma Company N.V. in more detail

NAMS trades at -9.3× next year's expected earnings, 89.2× sales. Measured against its own history, the price is 30% above what its usual multiples would imply ($14.83) — well above its usual price. It sits 10% below its 200-week average of $21.44.

Its Funk Score is 27 out of 100 (financial strength 7.9, profitability 0.0, growth 1.7, value 1.1, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

5 of the superinvestors tracked here hold NAMS, including Peter Kolchinsky (2.8% of the portfolio), Stanley Druckenmiller (2.4% of the portfolio), Lee Ainslie (1.0% of the portfolio).

Superinvestors holding NAMS

5 of the investors tracked here report a position in their latest 13F filing.

NewAmsterdam Pharma Company N.V. (NAMS): questions and answers

What is NewAmsterdam Pharma Company N.V.'s market cap?

NewAmsterdam Pharma Company N.V. is valued at $2.31B at a share price of $19.30.

Is NAMS overvalued or undervalued?

Against its own history, NAMS is well above its usual price: the price is 30% above the $14.83 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is NAMS above its 200-week moving average?

No. NAMS is 10.0% below its 200-week average of $21.44. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is NewAmsterdam Pharma Company N.V. growing?

Over the last three fiscal years NewAmsterdam Pharma Company N.V.'s revenue grew -39.7% a year.

Does NAMS pay a dividend?

NewAmsterdam Pharma Company N.V. does not currently pay a regular dividend.

Which famous investors own NAMS?

In their latest quarterly filings, Peter Kolchinsky (2.8% of the portfolio), Stanley Druckenmiller (2.4% of the portfolio), Lee Ainslie (1.0% of the portfolio), Andreas Halvorsen (0.4% of the portfolio), David Greenspan (0.1% of the portfolio) hold NAMS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “NewAmsterdam Pharma Company N.V. (NAMS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NAMS

Underlying data: Yahoo Finance; company filings with the SEC.